血小板活化在不同疾病（如癌症、2型糖尿病、阿尔茨海默病和心血管疾病，甚至在新冠肺炎患者中）的血栓病理过程中起着关键作用。因此，抗血小板治疗对于减少血栓形成至关重要。然而，当前抗血小板药物的效果有限。因此，寻找新的抗血小板化合物对于开发新药至关重要。在这个背景下，线粒体功能作为血小板活化所需的高效能源已被广泛认可。然而，作为抗血小板靶点的线粒体功能的贡献仍然未被充分开发。在此方面，羟醌衍生物的分子内氢键结合被描述为一种结构图案，可以使小分子到达线粒体，从而发挥抗血小板活性等作用。在本综述中，我们描述了线粒体功能在血小板活化中的作用，以及羟醌衍生物通过线粒体调控发挥抗血小板活性。版权所有 © 2023 Elsevier Ltd. 保留所有权利。

Platelet activation plays an essential role in the pathogenesis of thrombotic events in different diseases (e.g., cancer, type 2 diabetes, Alzheimer's, and cardiovascular diseases, and even in patients diagnosed with coronavirus disease 2019). Therefore, antiplatelet therapy is essential to reduce thrombus formation. However, the utility of current antiplatelet drugs is limited. Therefore, identifying novel antiplatelet compounds is very important in developing new drugs. In this context, the involvement of mitochondrial function as an efficient energy source required for platelet activation is currently accepted; however, its contribution as an antiplatelet target still has little been exploited. Regarding this, the intramolecular hydrogen bonding of hydroquinone derivatives has been described as a structural motif that allows the reach of small molecules at mitochondria, which can exert antiplatelet activity, among others. In this review, we describe the role of mitochondrial function in platelet activation and how hydroquinone derivatives exert antiplatelet activity through mitochondrial regulation.Copyright © 2023 Elsevier Ltd. All rights reserved.